赛马鲁肽
医学
炎症性肠病
减肥
肥胖
胃肠病学
疾病
克罗恩病
内科学
内分泌学
糖尿病
2型糖尿病
利拉鲁肽
作者
Aakash Desai,Himsikhar Khataniar,Jana G. Hashash,Francis A. Farraye,Miguel Regueiro,Gursimran Kochhar
摘要
Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown sustained and clinically significant weight loss in the general population. There are limited data on outcomes of its use in patients with inflammatory bowel disease (IBD).
科研通智能强力驱动
Strongly Powered by AbleSci AI
pluto
昏睡的蟠桃
cdercder
Oracle
qiao
bc
笨笨芯
平常的毛豆
小飞飞
iNk
研友_Y59785
wy.he
归尘
HEIKU
冰魂
科研小民工
Rye227
xiahou
余味
back you up
皖公网安备34019202002308
